Skip to content
PDC Therapeutics logo — Biotechnology start-up developing targeted Polymer-Drug Conj...

PDC Therapeutics

Biotechnology start-up developing targeted Polymer-Drug Conjugate platform technologies, named Sagitta®

Founded 2020 Switzerland Lausanne, Switzerland 4 employees Biotechnology

General Information

Company Name PDC Therapeutics
Founded Year 2020
Location Switzerland Lausanne, Switzerland
Employees 4
Industries Biotechnology
Social

BounceWatch is an independent company data service, not affiliated with PDC Therapeutics. To contact PDC Therapeutics, visit pdcbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does PDC Therapeutics compare?

A PDF of PDC Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting PDC Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About PDC Therapeutics

PDC Therapeutics is a biotechnology start-up founded in 2020 and headquartered in Switzerland. The company focuses on developing targeted Polymer-Drug Conjugate technologies under the proprietary Sagitta® platform, aiming to provide patients with an optimal therapeutic index. PDC Therapeutics collaborates with multinational pharmaceutical companies through co-development programs and is supported by an industry-experienced board of scientific and supervisory experts globally. The company's biodegradable conjugation platforms enable the discovery and development of therapies with versatile targeting capabilities. Currently, there is no public information available regarding the last investment or the involved investors.

Business keywords: Polymer-Drug Conjugate, Sagitta®, Therapeutics, Nanomedicines, Cancer Therapy, Biodegradable Conjugation, Drug Delivery, Co-development Programs, Pharmaceutical Industry, Targeted Therapies, Medical Research, Drug Development, Scientific Board, Biotech Start-up

No funding data available for PDC Therapeutics yet.

PDC Therapeutics Alternatives & Competitors

View All Alternatives
PDC Therapeutics vs

Clinically-validated biotech company for targeted therapies, disrupting the efficacy-toxicity trade-...

Series A
30 employees
Biotechnology, Pharmaceutical
PDC Therapeutics vs

Engineering the future of targeted medicines, breaking barriers to develop the next generation thera...

Post-IPO Equity
15 employees
Biotechnology, Health Care
PDC Therapeutics vs

Innovative solutions for precise MRI imaging and cancer treatment with advanced drug delivery and li...

Venture round
1 employees
Biotechnology, Life Sciences

FAQ About PDC Therapeutics

Biotechnology start-up developing targeted Polymer-Drug Conjugate platform technologies, named Sagitta®
PDC Therapeutics was founded in 2020.
PDC Therapeutics is headquartered in Lausanne, Switzerland.
PDC Therapeutics operates in Biotechnology. Its work centres on Polymer-Drug Conjugate, Sagitta®, Therapeutics and Nanomedicines.
PDC Therapeutics has approximately 4 employees.
Top alternatives and competitors to PDC Therapeutics include RS Research, VBL Therapeutics (Nasdaq:VBLT), Photobiotics, Bound Therapeutics, AC BioScience SA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PDC Therapeutics and RS Research are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for PDC Therapeutics, https://bouncewatch.com/company/pdc-therapeutics, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout